Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 5/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.44 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.43 |
| ▸ | CDK2 | P24941 | 2/20 | 0.43 |
| ▸ | CDK9 | P50750 | 2/20 | 0.43 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 2/20 | 0.40 |
| ▸ | JAK3 | P52333 | 2/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.40 |
| ▸ | IDH2 | P48735 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.39 |
| ▸ | CDK7 | P50613 | 1/20 | 0.39 |
| ▸ | CCNH | P51946 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16388783 | 0.89 | ROCK1 (0.47) | SYKROCK1CCNT1CDK2CDK9 | |
| SCHEMBL15102540 | 0.86 | IDH1 (0.53) | SYKPTGS2CCNT1CDK2CDK9 | |
| SCHEMBL29561157 | 0.86 | IDH1 (0.53) | SYKPTGS2CCNT1CDK2CDK9 | |
| SCHEMBL16388205 | 0.85 | SYK (0.53) | SYKROCK1PTGS2IDH2 | |
| SCHEMBL16391722 | 0.78 | SYK (0.44) | SYKROCK1PTGS2IDH2 | |
| SCHEMBL16388712 | 0.78 | IDH2 (0.48) | SYKROCK1CCNT1CDK2CDK9 | |
| SCHEMBL16388437 | 0.78 | IDH1 (0.49) | SYKPTGS2IDH2 | |
| SCHEMBL16388436 | 0.78 | IDH1 (0.52) | SYKIDH2 | |
| SCHEMBL16388429 | 0.77 | CDK9 (0.45) | SYKROCK1PTGS2CCNT1CDK2 | |
| SCHEMBL16388728 | 0.76 | SYK (0.60) | SYKROCK1PTGS2JAK2IDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3019490-B1 | N,6-BIS(ARYL OR HETEROARYL)-1,3,5-TRIAZINE-2,4-DIAMINE COMPOUNDS AS IDH2 MUTANTS INHIBITORS FOR THE TREATMENT OF CANCER | AGIOS PHARMACEUTICALS INC (US) | 2020-06-03 | — | — | EP | disclosed |
| US-20170348318-A1 | N,6-BIS(ARYL OR HETEROARYL)-1,3,5-TRIAZINE-2,4-DIAMINE COMPOUNDS AS IDH2 MUTANTS INHIBITORS FOR THE TREATMENT OF CANCER | SERVIER PHARMACEUTICALS LLC | 2017-12-07 | — | — | US | disclosed |
| US-20170348318-A1 | N,6-BIS(ARYL OR HETEROARYL)-1,3,5-TRIAZINE-2,4-DIAMINE COMPOUNDS AS IDH2 MUTANTS INHIBITORS FOR THE TREATMENT OF CANCER | SERVIER PHARMACEUTICALS LLC | 2017-12-07 | — | — | US | disclosed |
| US-9724350-B2 | N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as IDH2 mutants inhibitors for the treatment of cancer | AGIOS PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-9724350-B2 | N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as IDH2 mutants inhibitors for the treatment of cancer | AGIOS PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20160158241-A1 | N,6-BIS(ARYL OR HETEROARYL)-1,3,5-TRIAZINE-2,4-DIAMINE COMPOUNDS AS IDH2 MUTANTS INHIBITORS FOR THE TREATMENT OF CANCER | SERVIER PHARMACEUTICALS LLC | 2016-06-09 | — | — | US | disclosed |
| US-20160158241-A1 | N,6-BIS(ARYL OR HETEROARYL)-1,3,5-TRIAZINE-2,4-DIAMINE COMPOUNDS AS IDH2 MUTANTS INHIBITORS FOR THE TREATMENT OF CANCER | SERVIER PHARMACEUTICALS LLC | 2016-06-09 | — | — | US | disclosed |
| WO-2015006592-A1 | N,6-BIS(ARYL OR HETEROARYL)-1,3,5-TRIAZINE-2,4-DIAMINE COMPOUNDS AS IDH2 MUTANTS INHIBITORS FOR THE TREATMENT OF CANCER | AGIOS PHARMACEUTICALS, INC. (US) | 2015-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158241-A1 | N,6-BIS(ARYL OR HETEROARYL)-1,3,5-TRIAZINE-2,4-DIAMINE COMPOUNDS AS IDH2 MUTANTS INHIBITORS FOR THE TREATMENT OF CANCER | IDH2, IDH3B, IDH3A | SYK 3819/4885ROCK1 4053/4885PTGS2 1118/4885 |
| US-20170348318-A1 | N,6-BIS(ARYL OR HETEROARYL)-1,3,5-TRIAZINE-2,4-DIAMINE COMPOUNDS AS IDH2 MUTANTS INHIBITORS FOR THE TREATMENT OF CANCER | IDH2, IDH3B, IDH3A | SYK 3819/4885ROCK1 4053/4885PTGS2 1118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.